Table 3.
Ongoing studies on hepatocellular carcinoma.
| Trial (ClinicalTrials.gov identifier) | Setting | Phase | Study interventions | Number of patients | Primary endpoint |
|---|---|---|---|---|---|
| Checkpoint inhibitors | |||||
| NCT02576509 CheckMate459 | 1st line | III | Nivolumab versus sorafenib in first line | 726 | OS, ORR |
| NCT02702414 Keynote 224 | 2nd line | II | Pembrolizumab in second line | 100 | ORR |
| NCT02702401 Keynote 240 | 2nd line | III | Pembrolizumab versus BSC in second line | 408 | PFS, OS |
| NCT01658878 CheckMate 040 | I/II | Nivolumab versus nivolumab + Ipilimumab nivolumab | 620 | AEs, SAEs, ORR | |
| NCT02519348 | Advanced | II | Tremelimumab + MEDI4736 versus tremelimumab versus MEDI4736 | 144 | AEs, SAEs, DLTs |
| Vaccines | |||||
| NCT01974661 | Advanced | I | COMBIG-DC (allogeneic dendritic cells) cancer vaccine | 18 | Safety and tolerability |
| Cytokines | |||||
| NCT02632188 | Resected | I/II | SURGERY → DC-PMAT treatment | 60 | PFS |
| NCT02873442 | Advanced | I/II | TACE versus TACE + precision cell immunotherapy | 40 | PFS, OS |
| NCT02487017 | Advanced | II | TACE versus TACE + DK-CIK | OS | |
| CAR-T cells | |||||
| NCT02729493 | Advanced | II | EPCAM-targeted CAR-T cells | 25 | DCR |